Pharmaceuticals News

Envudeucitinib long-term Phase 3 data for treatment of plaque psoriasis, delivering highest reported PASI 100 Skin Clearance among oral therapies

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward...

Second Quarter 2026 and Selected Highlights:  Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million...

MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...

Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first...

Overname van Ouro Medicines samen met Gilead Sciences afgerond om potentiële first- en best-in-class T-cel-engager verder te ontwikkelen Ten minste €1,6 miljard aan liquide middelen verwacht over te...

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash...

- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly...